Skye Bio­science up­lists; On­coX's li­cens­ing deal with AB­VC Bio­Phar­ma

Plus, news about Zevra Ther­a­peu­tics and YS Bio­phar­ma:

Skye Bio­science up­lists to the Nas­daq: The San Diego biotech $SKYE is set to make the move from the OTC mar­kets on Thurs­day. Ear­li­er this year, it raised a to­tal of about $90 mil­lion in pri­vate place­ments. Skye re­cent­ly com­plet­ed en­roll­ment in a Phase 2a tri­al in glau­co­ma and oc­u­lar hy­per­ten­sion, and it plans to start an obe­si­ty and chron­ic kid­ney dis­ease study in the mid­dle of this year. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER